This page was last updated on 26 July 2021.
ANSTO is committed to supporting the health and well being of its people, partners, customers, and communities and will continue to follow government advice in response to the COVID pandemic.
ANSTO is the home of Australia's only nuclear reactor, our most significant research infrastructure and the advanced manufacturing of nuclear medicines that are likely to benefit all Australians at some point in their lifetime. Because of our unique operations and the health products we provide to the wider community, where possible, we have maintained operations during COVID.
We have also made adjustments to the services we provide to the scientific community and customers. We are working hard to also continue to support teachers across Australia with video conferencing to help Australian students progress their studies in science, with a particular focus on senior students.
User services for research and industry
Please refer to the user access page below for COVID-19 updates and accessing ANSTO's Research facilities.
Public tours and School group tours
ANSTO tour and school holiday programs in Sydney have been cancelled due to COVID-19 restrictions. Please contact the Discovery Centre if you have any questions.
Products and services
Client meetings will continue to be conducted via video conferencing however, laboratory testing, process development and pilot plant work programs are suspended until further notice.
We'll continue to provide regular updates directly with our clients.
Nuclear Waste Solutions
We have postponed a range of Sydney-based projects. Those impacted have been contacted and will be kept up to date with any significant changes.
Some training courses have been cancelled. We are reaching out to those impacted to reschedule their booking.
Calibrations for essential places of work, such as hospitals, continue and consultancy services in fieldwork and laboratory analysis have been suspended until restrictions are lifted.
If you require more information or assistance please contact our team via email@example.com or call +61 2 9717 3251.
Business operations continue however shipments are being impacted by COVID-19. We are in touch with customers and will provide updates as soon as they are readily available.
At this time, we have deferred all on site based Synroc activities. The Synroc team will continue to operate remotely to deliver on stakeholder requirements and will be in touch with clients directly should there be any relevant changes.
COVID-19 transmission within nuclear medicine presents a risk to the security of supply.
To mitigate risk, we have altered staffing arrangements, similar to 2020’s COVID-19 operations. This will impact nuclear medicine supply for domestic and export customers from 2 August. Read the full update here and, as always, please do reach out with any questions.